Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors - Hit to lead exploration

  • Vibha Oza
  • , Susan Ashwell
  • , Patrick Brassil
  • , Jason Breed
  • , Chun Deng
  • , Jay Ezhuthachan
  • , Heather Haye
  • , Candice Horn
  • , James Janetka
  • , Paul Lyne
  • , Nicholas Newcombe
  • , Ludo Otterbien
  • , Martin Pass
  • , Jon Read
  • , Sian Roswell
  • , Mei Su
  • , Dorin Toader
  • , Dingwei Yu
  • , Yan Yu
  • , Anna Valentine
  • Peter Webborn, Ann White, Sonya Zabludoff, Xiaolan Zheng

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Checkpoint Kinase-1 (Chk1, CHK1, CHEK1) is a Ser/Thr protein kinase that mediates cellular responses to DNA-damage. A novel class of Chk1 inhibitors, triazoloquinolones/triazolones (TZ's) was identified by high throughput screening. The optimization of these hits to provide a lead series is described.

Original languageEnglish
Pages (from-to)5133-5138
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume20
Issue number17
DOIs
StatePublished - Sep 1 2010

Keywords

  • CHK1
  • Checkpoint Kinase inhibitors
  • Triazolones

Fingerprint

Dive into the research topics of 'Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors - Hit to lead exploration'. Together they form a unique fingerprint.

Cite this